Press Release New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC 27 April 2025
Press Release New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC 27 April 2025
Press Release GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights 27 April 2025
Press Release KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma 27 April 2025
Press Release FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights 27 April 2025
Press Release RC Deadline: Rosen Law Firm Urges Ready Capital Corporation (NYSE: RC) Stockholders to Contact the Firm for Information About Their Rights 27 April 2025
Press Release Lead Plaintiff Deadline on May 12, 2025 for GERN Investors – Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm 27 April 2025
Press Release MRVI Deadline: Rosen Law Firm Urges Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) Stockholders to Contact the Firm for Information About Their Rights 27 April 2025
